UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.

Yair Lotan, MD, discusses ongoing research with novel agents in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Yair Lotan, MD, discusses notable up-and-coming agents in the BCG-unresponsive non–muscle-invasive bladder cancer treatment armamentarium.

Neoadjuvant sotigalimab plus chemoradiotherapy is safe and feasible compared with chemoradiotherapy alone in patients with rectal cancer.

Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.

Vijayakrishna Gadi, MD, PhD, presents the case of a 54-year-old woman with HER2-positive metastatic breast cancer exhibiting bone, liver, and brain lesions, and key opinion leaders share their perspectives on the most appropriate treatment approaches tailored to the patient's specific disease characteristics and metastatic sites.

Vijayakrishna Gadi, MD, PhD, shares his insights on managing patients with HER2-positive metastatic breast cancer who have progressed on second and third-line treatments, stressing the potential benefits of incorporating small molecules, tyrosine kinase inhibitors (TKIs), chemotherapy, and enrolling patients in clinical trials to optimize outcomes.

Tiffany A. Traina, MD, addresses adverse event monitoring and the range of adverse events patients may experience with front-line treatments for HER2-positive metastatic breast cancer, particularly highlighting alopecia and diarrhea as common side effects.

Key opinion leaders explore various therapeutic options for later-line treatment of HER2-positive metastatic breast cancer, emphasizing the significance of the HER2CLIMB and CLEOPATRA trials, while also drawing comparisons to real-world data to inform clinical decision-making.

Tiffany A. Traina, MD, presents a patient case involving a woman diagnosed with HR-negative, HER2 3+ invasive ductal adenocarcinoma and elaborates on the clinical management approaches employed in her treatment sequencing.

Heather McArthur, MD, emphasizes the influence of recent and ongoing clinical trials, specifically DESTINY-Breast09 and HER2CLIMB-05, in steering the treatment paradigm in 1st-line HER2-positive metastatic breast cancer.

Medical experts examine the current standards of care and successive lines of treatment for HER2-positive metastatic breast cancer, while also addressing the challenges encountered in managing this complex disease.

Tiffany A. Traina, MD; Vijayakrishna Gadi, MD, PhD, and Heather McArthur, MD, underscore the importance of testing all early-stage and breast cancer patients for HER2 positivity to inform and guide optimal therapeutic decision-making.

Carlos L. Arteaga, MD, discusses the utility of vepdegestrant alone or in combination in patients with ER-positive, HER2-negative advanced breast cancer.

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Nina Sanford, MD, discusses how radiation could help improve QOL for patients with rectal cancer and situations when radiation or surgery could be omitted.

Tian Zhang, MD, MHS, discusses areas of ongoing debate regarding prostate cancer management.

Tian Zhang, MD, MHS, discusses the implications of subgroup analyses from the KEYNOTE-564 trial in patients with renal cell carcinoma.

Tian Zhang, MD, MHS, discusses using the adjuvant KEYNOTE-564 regimen to treat high-risk patients with renal cell carcinoma.

Drs Camidge and Gerber highlight the ways that a liberal arts education can lay the foundation for a successful career in academic medicine; the importance and various forms of mentorship; and how clinical investigators can use their experiences and data to drive national policy changes.

Qian (Janie) Qin, MD, discusses upcoming areas of interest in the renal cell carcinoma armamentarium.

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Vitaly Margulis, MD, expands on the factors to consider when treating patients with advanced RCC and how these could help inform the selection of immunotherapy-based combinations in the frontline setting.

Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.

Hans Hammers, MD, PhD, discusses a case presentation of a patient with advanced renal cell carcinoma.

Jue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.

Jue Wang, MD, discusses the importance of personalized treatment approaches in patients with relapsed or refractory urothelial carcinoma.

David Sher, MD, discusses efficacy outcomes with daily adaptive radiotherapy with 1-mm planning target volume margins in patients with head and neck squamous cell carcinoma.

Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.

Neil Desai, MD, discusses the potential benefits and limitations of utilizing chemoradiation or triple modality therapy for bladder preservation in the upfront management of patients with locally advanced, nonmetastatic muscle-invasive bladder cancer.